Anebulo Pharmaceuticals, Inc. Common Stock
ANEBAnebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare and unmet medical conditions, particularly those related to substance use disorders. The company's lead candidate aims to address acute cannabinoid overdose and other drug-related toxicity, leveraging its proprietary research and development platform.
Company News
A comprehensive market research report analyzing the Cannabis Use Disorder pipeline, featuring over 5 companies developing novel treatments for addressing CUD challenges.
Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc. Assembly Biosciences, Inc. (NASDAQ: ASMB) gained 120% to $1.5982 after the company and Gilead announced they entered into a 12-year partnership to advance the research and...
Here is how Exact Sciences (EXAS) and Anebulo Pharmaceuticals, Inc. (ANEB) have performed compared to their sector so far this year.
H.C. Wainwright has initiated coverage on Anebulo Pharmaceuticals Inc (NASDAQ: ANEB) with a Buy rating and a price target of $6. Anebulo Pharmaceuticals is an emerging specialty biopharmaceutical company with a primary focus on developing therapy for acute cannabinoid intoxication (ACI), presenting a unique opportunity as approximately 2.1 mi...
